Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC |
Hackman Jeffrey S.Director · Chief Executive Officer
|
GrantCommon Shares | 2,224 | $5.53 | $12,298.72 |
DisclosureSEC source: 0001926254-26-000018 · form4-10132026_041008.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,685 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 3,846 | $5.53 | $21,268.38 |
DisclosureSEC source: 0002043395-26-000016 · form4-10132026_041010.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,533 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 3,946 | $5.53 | $21,821.38 |
DisclosureSEC source: 0002043411-26-000018 · form4-10132026_041003.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,746 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 2,326 | $5.53 | $12,862.78 |
DisclosureSEC source: 0002043317-26-000016 · form4-10132026_041005.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,013 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
GrantCommon shares | 3,846 | $5.53 | $21,268.38 |
DisclosureSEC source: 0001468308-26-000034 · form4-10132026_041001.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,855 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC |
Hackman Jeffrey S.Director · Chief Executive Officer
|
GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000016 · form4-10012026_041005.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,461 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000032 · form4-10012026_041001.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,009 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000014 · form4-10012026_041007.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,687 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0002043411-26-000016 · form4-10012026_041003.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,800 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043395-26-000014 · form4-10012026_041009.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,687 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC |
Brughera Marco MariaDirector
|
Exercise / conversionStock Option · Derivative | 15,545 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · derivative · entry 3 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,000 Underlying: Common shares · 15,545 shares Expires 2026-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC |
Brughera Marco MariaDirector
|
SaleCommon Shares | 15,545 | $10.29 | $159,958.05 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · nonDerivative · entry 2 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC |
Brughera Marco MariaDirector
|
Exercise / conversionCommon Shares | 15,545 | $2.11 | $32,799.95 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · nonDerivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:05 UTC |
Raykov RostyFormer Director
|
SaleCommon shares | 10,000 | $12.11 | $121,100.00 |
DisclosureSEC source: 0001468316-26-000023 · form4-09012026_040901.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,411 F2 · security: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:15 UTC |
Sayad Pierre SargisChief Medical Officer
|
SaleCommon Shares | 12,000 | $12.18 | $146,160.00 |
DisclosureSEC source: 0002043395-26-000012 · form4-09012026_120920.xml · nonDerivative · entry 2 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,519 F2 · security: Represents sale of previously vested restricted shares and vested performance shares. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:15 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043395-26-000012 · form4-09012026_120920.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,519 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:13 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000012 · form4-09012026_120948.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,519 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:12 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0002043411-26-000014 · form4-09012026_120925.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,644 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:09 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000030 · form4-09012026_120910.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,306 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:10 UTC |
Hackman Jeffrey S.Director · Chief Executive Officer
|
GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000014 · form4-09012026_120929.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,302 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:05 UTC |
Raykov RostyFormer Director
|
GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000023 · form4-09012026_040901.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,411 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 21:42 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
Exercise / conversionStock Options · Derivative | 21,928 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · derivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 779,330 Underlying: Common Shares · 21,928 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 21:42 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon shares | 21,928 | $5.10 | $111,832.80 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 21:42 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
SaleCommon shares | 75,000 | $11.78 | $883,500.00 |
DisclosureSEC source: 0001468308-26-000028 · form4-08282026_090813.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,675 F1 · security: Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 20:05 UTC |
Raykov RostyFormer Director
|
SaleCommon shares | 10,000 | $9.58 | $95,800.00 |
DisclosureSEC source: 0001468316-26-000021 · form4-08042026_040802.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,633 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043395-26-000010 · form4-08032026_040811.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,351 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000010 · form4-08032026_040809.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,351 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0002043411-26-000012 · form4-08032026_040808.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,488 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Raykov RostyFormer Director
|
GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000019 · form4-08032026_040804.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,633 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000026 · form4-08032026_040801.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,675 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC |
Hackman Jeffrey S.Director · Chief Executive Officer
|
GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000012 · form4-08032026_040806.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,143 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC |
Raykov RostyFormer Director
|
Exercise / conversionStock Options · Derivative | 15,597 | $2.45 Strike: $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525,000 Underlying: options · 15,597 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC |
Raykov RostyFormer Director
|
SaleCommon shares | 9,599 | $10.41 | $99,925.59 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,855 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC |
Raykov RostyFormer Director
|
Exercise / conversionCommon shares | 15,597 | $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC |
Raykov RostyFormer Director
|
GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,857 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:37 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043395-26-000008 · form4-07012026_080722.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,183 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:34 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0002043411-26-000010 · form4-07012026_080757.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,332 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:38 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000008 · form4-07012026_080754.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,183 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:35 UTC |
Andrade RobertCHIEF FINANCIAL OFFICER
|
GrantCommon shares | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001468308-26-000024 · form4-07012026_080710.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,972 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:36 UTC |
Hackman Jeffrey S.Director · Chief Executive Officer
|
GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000010 · form4-07012026_080713.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,984 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 10, 2026 Filed Jun 10, 2026 21:26 UTC |
Islam KhalidDirector
|
GrantStock Option · Derivative | 25,000 | $8.70 Strike: $8.70 | $217,500.00 |
DisclosureSEC source: 0001701858-26-000002 · form4-06102026_090631.xml · derivative · entry 1 Islam Khalid · CIK 0001701858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 25,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 10, 2026 Filed Jun 10, 2026 21:24 UTC |
RALLIS CHRIS ADirector
|
GrantStock Option · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001185945-26-000004 · form4-06102026_090645.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 10, 2026 Filed Jun 10, 2026 21:50 UTC |
Brughera Marco MariaDirector
|
GrantStock Option · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001589776-26-000002 · form4-06102026_090632.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,545 Underlying: Common shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 10, 2026 Filed Jun 10, 2026 21:27 UTC |
Cook Jodi ADirector
|
GrantStock Options · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001791004-26-000002 · form4-06102026_090632.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC |
Raykov RostyDirector
|
Exercise / conversionStock Options · Derivative | 15,597 | $2.45 Strike: $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,556,195 Underlying: options · 15,597 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC |
Raykov RostyDirector
|
SaleCommon shares | 9,747 | $9.62 | $93,766.14 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,079 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC |
Raykov RostyDirector
|
Exercise / conversionCommon shares | 15,597 | $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC |
Sayad Pierre SargisChief Medical Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043395-26-000006 · form4-06012026_040605.xml · nonDerivative · entry 1 Sayad Pierre Sargis · CIK 0002043395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,015 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC |
Cioffi Christiana MarieChief Strategy Officer
|
GrantCommon shares | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0002043411-26-000008 · form4-06012026_040609.xml · nonDerivative · entry 1 Cioffi Christiana Marie · CIK 0002043411 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,176 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC |
Evans Terry LChief Commercial Officer
|
GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000006 · form4-06012026_040607.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,015 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.